WORCESTER, Mass., March 17, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that study results in respect of Generex Oral-lyn(tm), the Company’s proprietary oral insulin spray product, will be the subject of a podium presentation at the 69th American Diabetes Association (ADA) Scientific Sessions (www.diabetes.org) in June.
